-
Regulatory, Safety & Market Access
-
Regulatory, Safety & Market Access
-Understand evolving global regulatory frameworks specific to oligonucleotides and peptides, includi
...
-
Peptide CMC & Process Development
-
Peptide CMC & Process Development
The GLP-1 Manufacturing Experience, Peptide Process Development for High-Demand Global Supply
-
Regulatory, Safety & Market Access
-
Regulatory, Safety & Market Access
Explore how early planning for CMC—covering formulation, stability, and release specifications—can a
...
-
Regulatory, Safety & Market Access
-
Regulatory, Safety & Market Access
Understanding FDA, EMA, and CDSCO expectations for oligonucleotide-based therapies and how they diff
...
-
Innovation in Therapeutic Modalities
-
Innovation in Therapeutic Modalities
How Junevity is leveraging novel biomaterials, nanocarriers, and tissue-specific strategies to impro
...
-
Translational & Clinical Strategy
-
Translational & Clinical Strategy
Examine regulatory expectations and case studies on toxicity pathways specific to oligonucleotides a
...
-
Innovation in Therapeutic Modalities
-
Innovation in Therapeutic Modalities
Explore how oligonucleotides are evolving beyond traditional antisense and siRNA mechanisms into are
...
-
Peptide CMC & Process Development
-
Peptide CMC & Process Development
-
Peptide CMC & Process Development
-
Peptide CMC & Process Development
Integrating peptide ligands into AAV capsids to enhance targeted delivery and cellular uptake, incre
...
-
Translational & Clinical Strategy
-
Translational & Clinical Strategy
This first-in-class small molecule activates the creatine-driven thermogenic pathway, offering a nov
...
-
Oligonucleotide CMC & Process Development
-
Oligonucleotide CMC & Process Development
GRN‑1 leverages a lipid nanoparticle delivery system to deliver mRNA therapeutics targeting metaboli
...
-
Regulatory, Safety & Market Access
-
Regulatory, Safety & Market Access
Exploring recent regulatory feedback, emerging global frameworks, safety concerns including off-targ
...
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
Afternoon Refreshments
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
Evening Drinks Reception
-
Oligonucleotide CMC & Process Development
-
Oligonucleotide CMC & Process Development
Examine regulatory expectations and case studies on toxicity pathways specific to oligonucleotides a
...
-
Innovation in Therapeutic Modalities
-
Innovation in Therapeutic Modalities
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
1-2-1 Meetings/Networking Break
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
1-2-1 Meetings/Networking Break
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
Networking Lunch
-
Translational & Clinical Strategy
-
Translational & Clinical Strategy
Dive into the design of peptides with tunable biological activity, including switchable conformation
...
-
Oligonucleotide CMC & Process Development
-
Oligonucleotide CMC & Process Development
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
Morning Refreshments
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
1-2-1 Meetings/Networking Break
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
1-2-1 Meetings/Networking Break
-
Peptide CMC & Process Development
-
Peptide CMC & Process Development
Stem cells used in novel cell therapies for respiratory, orthopedic, and wound healing indications n
...
-
-
Innovation in Therapeutic Modalities
-
Translational & Clinical Strategy
-
Oligonucleotide CMC & Process Development
-
Peptide CMC & Process Development
-
Regulatory, Safety & Market Access
Registration
-
Translational & Clinical Strategy
-
Translational & Clinical Strategy
Explore the latest advancements in oligo-based therapeutics including ASOs, siRNA, gRNA, miRNA, apta
...
-
Innovation in Therapeutic Modalities
-
Innovation in Therapeutic Modalities
Circular DNA exists as an endogenous molecule in human cells with emerging relevance to health and d
...
-
Oligonucleotide CMC & Process Development
-
Oligonucleotide CMC & Process Development
Manufacturing of long RNA oligos: Synthesis and analytical strategies and challenges Scaling Up Oli
...
)
)
)
)
)
)
)
)
)
)
